Section Arrow
EOLS.NASDAQ
- Evolus
Quotes are at least 15-min delayed:2026/02/10 05:55 EST
Pre Market
Last
 4.29
+0.05 (+1.18%)
Bid
4.28
Ask
4.4
High 4.3 
Low 4.24 
Volume 4.40K 
Regular Hours (Closed)
Last
 4.24
-0.26 (-5.78%)
Day High 
4.52 
Prev. Close
4.5 
1-M High
6.04 
Volume 
1.19M 
Bid
4.28
Ask
4.4
Day Low
4.2 
Open
4.51 
1-M Low
4.405 
Market Cap 
291.69M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.7 
20-SMA 4.97 
50-SMA 6.06 
52-W High 17.12 
52-W Low 4.405 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.90/0.41
Enterprise Value
419.95M
Balance Sheet
Book Value Per Share
-0.44
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
266.27M
Operating Revenue Per Share
2.85
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health19.33-3.69-16.03%36.28PE
Pre Market 18.8 -0.53 -2.74%
VTRSViatris15.56+0.98+6.72%227.2PE
Pre Market 15.59 +0.03 +0.19%
BFRIBiofrontera0.8103-0.0107-1.30%0.74PE
Pre Market 0.7424 -0.0679 -8.38%
CGCCanopy Growth Corp1.09-0.01-0.91%-- 
Pre Market 1.11 +0.02 +1.83%
HLNHaleon plc10.88-0.1-0.91%23.79PE
Pre Market 10.85 -0.03 -0.28%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.